CVS Health (NYSE:CVS) Price Target Raised to $106.00

CVS Health (NYSE:CVS) had its target price raised by investment analysts at Barclays from $101.00 to $106.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The firm presently has an “overweight” rating on the pharmacy operator’s stock. Barclays‘s target price points to a potential upside of 13.32% from the company’s previous close.

CVS has been the subject of several other research reports. Truist Financial boosted their target price on CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Royal Bank Of Canada raised their target price on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. The Goldman Sachs Group upped their target price on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.88.

CVS Health Trading Up 0.3%

NYSE CVS opened at $93.54 on Tuesday. The company’s 50-day moving average price is $80.73 and its 200-day moving average price is $79.19. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market cap of $119.35 billion, a PE ratio of 41.21, a PEG ratio of 0.91 and a beta of 0.60. CVS Health has a 12 month low of $58.50 and a 12 month high of $98.43.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the firm earned $2.25 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts forecast that CVS Health will post 7.44 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock worth $323,703,977 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CVS Health

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock worth $9,579,508,000 after buying an additional 1,824,424 shares during the last quarter. Capital World Investors boosted its holdings in shares of CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after buying an additional 1,419,575 shares during the period. State Street Corp raised its stake in shares of CVS Health by 2.1% in the fourth quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after acquiring an additional 1,245,457 shares during the last quarter. Capital International Investors grew its position in shares of CVS Health by 3.4% in the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after purchasing an additional 900,153 shares during the period. Finally, Invesco Ltd. grew its stake in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.